Monitoring Inhibitor Patients With the Right Assays

Seminars in Hematology

Volumn 45, Issue SUPPL. 1, 2008, Pages

  Barrowcliffe, Trevor W ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN;

ANTIBODY TITER; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; DRUG DETERMINATION; HEMOPHILIA; HEMOPHILIA A; HUMAN; LABORATORY TEST; OUTCOME ASSESSMENT; PATIENT MONITORING; PLASMA TRANSFUSION; PRIORITY JOURNAL; REPRODUCIBILITY; THROMBIN TIME; THROMBOELASTOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 44649171504     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.03.002     Document Type: Article

References (31)

1. DiMichele D. Inhibitors to factor VIII-Epidemiology and treatment. In: Lee C.A., Berntorp E., and Hoots W.K. (Eds). Textbook of Haemophilia (2005), Blackwell, Oxford, UK 64-70
2. Kasper C.K., Aledort L., Aronson D., Counts R., Edson J.R., van Eys J., et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34 (1975) 612
3. Austen D.E., Lechner K., Rizza C.R., and Rhymes I.L. A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost 47 (1982) 72-75
4. Verbruggen B., Novakova I., Wessels H., Boezeman J., van den Berg M., and Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability. Thromb Haemost 73 (1995) 247-251
5. Giles A.R., Verbruggen B., Rivard G.E., Teitel J., and Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemost 79 (1998) 872-875
6. Verbruggen B., and Meijer P. Performance of Bethesda assay and Nijmegen variant in external quality assessment (ECAT) of factor VIII inhibitor assays. J Thromb Haemost 5 suppl 2 (2007) O-T-093
7. Raut S: A collaborative study of factor VIII inhibitors. Potters Bar, Hertfordshire, UK, National Institute for Biological Standards and Control, unpublished report, 2005
8. Littlewood J.D., Bevan S.A., Kemball-Cook G., Evans R.J., and Barrowcliffe T.W. Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors. Br J Haematol 77 (1991) 535-538
9. Gensana M., Altisent C., Aznar J.A., Casaña P., Hernández F., Jorquera J.I., et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 7 (2001) 369-374
10. Morrissey J.H., Macik B.G., Neuenschwander P.F., and Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81 (1993) 734-744
11. Johannessen M., Nielsen G., and Nordfang O. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). Blood Coagul Fibrinolysis 11 suppl 1 (2000) S159-S164
12. Santagostino E., Morfini M., Rocino A., Baudo F., Scaraggi F.A., and Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 86 (2001) 954-958
13. Cid A.R., Lorenzo J.I., Haya S., Montoro J.M., Casaña P., and Aznar J.A. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia 7 (2001) 39-41
14. Goudemand J., Caron C., Dreyfus M., Sie P., and Haemostasis Standardization Group of the Groupe d'Etude Hémostase et Thrombose. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagul Fibrinolysis 14 (2003) 505-511
15. Hemker H.C. The mode of action of heparin in plasma. In: Verstraete M., Vermylen J., Lijnen R., and Arnout J. (Eds). Thrombosis and Haemostasis (1987), Leuven University Press, Leuven, Belgium 17-36
16. Hemker H.C., Wielders S., Kessels H., and Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 70 (1993) 617-624
17. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., Wagenvoord R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
18. McIntosh J.H. Studies of the thrombin generation test in haemophilia (2003) PhD Thesis, University of London
19. MacFarlane R.G., and Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol 6 (1953) 3-8
20. Barrowcliffe T.W., Kemball-Cook G., and Gray E. Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med 101 (1983) 34-43
21. McIntosh J.H., Owens D., Lee C.A., Raut S., and Barrowcliffe T.W. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost 1 (2003) 1005-1011
22. Livnat T., Zivelin A., Martinowitz U., Salomon O., and Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost 4 (2006) 192-200
23. Dargaud Y., Lienhart A., and Negrier C. Monitoring of recombinant FVIIa by thrombin generation test. J Thromb Haemost 5 (2007) P-M-176 (suppl 2, abstr)
24. Eichinger S., Lubsczyk B., Gleiss A., Quehenberger P., and Kyrle P.A. Effects of recombinant factor VIIa (NovoSeven) on restoring thrombin generation in patients with haemophilia A and antibodies to factor VIII. J Thromb Haemost 5 suppl 2 (2007) P-S-176
25. van Veen J.J., Gatt A., Bowyer A., Cooper P.C., Kitchen S., and Makris M. Thrombin generation to monitor inhibitor bypass agents requires low concentrations of tissue factor (TF). J Thromb Haemost 5 suppl 2 (2007) P-W-152
26. Windyga J., Varadi K., Baran B., Keil B., and Turecek P. The effect of APCC and PCC on the generation of thrombin in haemophilia A patients with FVIII inhibitor: A cross-over pharmacokinetic study. J Thromb Haemost 5 suppl 2 (2007) P-W-118
27. Kenet G., Stenmo C.B., Blemings A., Wegert W., Goudemand J., Krause M., et al. Intra-subject variability of thromboelastographic parameters following rFVIIa in vivo administration in haemophilia patients: a multi-centre, randomized trial. J Thromb Haemost 5 suppl 2 (2007) P-T-164
28. Viuff D., Ezban M., Lind V., Dillow A., Raymer R., Merricks E., et al. Effect of rFVIIa and NN1731 (rFVIIa analogue) on thromboelastography (TEG) in whole blood obtained from haemophilia A dogs. J Thromb Haemost 5 suppl 2 (2007) P-W-113
29. Larsen L.F., Ezban M., Hedner U., Nicolaisen E.M., and Tengborn L. A whole blood clotting method measuring ex vivo effects of rFVIIa and FVIII in haemophilia blood. J Thromb Haemost 5 suppl 2 (2007) P-M-139
30. Elm T., Ezban M., and Tranholm M. Whole blood clotting time (WBCT) compared to in vivo dose response of rFVIIa in FVIII-KO mice. J Thromb Haemost 5 suppl 2 (2007) P-S-178
31. Bordet J., Plantier J., Ovanesov M., Volpert V., Ataullakhanov F., and Negrier C. Wall clot growth in plasma: effect of high doses of recombinant FVIIa. J Thromb Haemost 5 suppl 2 (2007) P-M-170